Dalteparin in Preventing DVT in Participants With Cancer

Completed · Not applicable

Conditions studied: Bone Sarcoma, Femur Fracture, Lymphoma, Metastatic Neoplasm, Pathologic Fracture, Plasma Cell Myeloma, Soft Tissue Sarcoma

In brief

This trial studies how well dalteparin works in preventing deep vein thrombosis (DVT) (blood clots) in participants with cancer. Dalteparin is a blood thinner that can treat blood clots and may prevent them from forming.

Key facts

Study ID

NCT00525057

Run by

M.D. Anderson Cancer Center

People needed

65

Starts

2006-07-07

Expected to finish

2020-06-19

Last updated by the study team

2021-01-22

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• GROUP A
• Metastatic disease, myeloma, lymphoma.
• Pathologic fracture or impending pathologic fracture of the femur.
• Intramedullary rod, plating, cementation, hip arthroplasty, or knee arthroplasty.
• GROUP B
• Primary sarcoma of bone or soft tissue of the lower extremity.
• T2 tumor (> 5 cm by < 20 cm).
• Radical resection of tumor, which may necessitate major bone or soft tissue reconstruction.

You may not qualify if…

• Presence of DVT on pre-operative screening ultrasound study.
• Massive tumor (> 20 cm in greatest dimension).
• Amputation of the affected leg as treatment of tumor.
• Estimated blood loss > 2 liters during surgery.
• Surgical drain output > 500 cc of bloody fluid during first 8 hours.
• International normalized ratio (I.N.R.) > 1.3 pre-operatively or > 1.5 post-operatively.
• Platelet count < 100,000 either pre-operatively or post-operatively.
• Indwelling post-operative epidural catheter for pain control.
• History of underlying bleeding disorder, such as hemophilia.
• History of adverse reaction to heparin such as heparin-induced thrombocytopenia.
• Severe liver or renal insufficiency.
• History of hypertensive or diabetic retinopathy.
• History of gastro-intestinal bleeding within 12 months.
• Treatment with warfarin, clopidogrel, aspirin, nonsteroidal antiinflammatory drugs (NSAIDs), low molecular weight heparin (LMWH) or other anti-coagulants for conditions.
• History of stroke.
• Women of child bearing potential having a positive urine or serum pregnancy test (human chorionic gonadotropin [hCG]) at the time of pre-operative evaluation (within 7 days of surgery).
• Women who are breastfeeding.
• Hemoglobin < 8.0 g/dL.
• Platelet count < 100,000/L.
• Alanine aminotransferase > 100 IU/L.
• Aspartate aminotransferase > 100 IU/L.
• Direct bilirubin > 0.5mg/dL.
• Serum creatinine > 2.0 mg/dL.
• Patients taking COX-2 inhibitors.
• Patients who have fragmented mechanical heart valves.

Where it is running

• M D Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.